MicroPort® CRM Announces the Launch of TALENTIA™ and ENERGYA™, ICDs and CRT-Ds Ranges and Their New Tablet Programmer Interface in Europe

Clamart, France,April 18, 2024 - MicroPort^® CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, announces the launch in Europe of TALENTIA^™ and ENERGYA^™, their new range of Implantable Cardiac Defibrillators (ICDs) and Cardiac Resynchronization Therapy and Defibrillation devices (CRT-Ds), featuring Bluetooth^®1 connectivity.

Simultaneously with the release of TALENTIA^™ and ENERGYA^™ ranges, MicroPort^® CRM launches a new user interface dedicated to their ICDs and CRT-Ds. The very modern "look and feel" interface perfectly suits to their SmartTouch™ tablet programmer.

Benoît Clinchamps, President of MicroPort® CRM, stated: "These new Bluetooth-enabled ICDs and CRT-Ds, incorporating state-of-the-art technology and exceptional longevity, alongside a modern and user-friendly programmer interface, highlight MicroPort® CRM's dedication to enhancing device connectivity and providing advanced patient care".

The first implantation, a TALENTIA™ 4LV CRT-D SonR® system, was successfully completed by Doctor Fernando López, a cardiologist from the Arrhythmia Unit at Hospital Universitario Central de Asturias (HUCA), led by Doctor José Manuel Rubín, in Oviedo, Spain on Wednesday, April 17, 2024.

The team commented: "Since our participation in the RESPOND-CRT⁴ trial we have always trusted in SonR® technology to automatically optimize cardiac resynchronization parameters, at rest and during exercise. Now, with the new interface on the MicroPort® tablet programmer, we have in hands advanced tools for following-up our patients who have been implanted with their defibrillators. Furthermore, their devices ensure smooth patient care by transmitting device data effortlessly via the dedicated mobile remote monitor."

TALENTIA^™ and ENERGYA^™ ranges enable wireless communication via Bluetooth^®, allowing for tablet-based programming and remote monitoring. These devices also feature several advanced functionalities such as: the Lead Parameter Evaluation (LPE) algorithm, the new monitoring alert on defibrillation leads, PARAD+^™ arrhythmia discrimination algorithm with the clinically proven lowest rate of inappropriate shocks², and AutoMRI^™, a function that automatically switches the device into a specific mode to protect patients during Magnetic Resonance Imaging (MRI) examinations³. These devices are also approved for 1.5 Tesla (T) and 3T MRI compatibility.

SonR^®, a unique hemodynamic sensor measuring the contractility of the left ventricle is a MicroPort® exclusivity available on TALENTIA^™ CRT-D SonR^®. The SonR^® system is the first and only CRT hemodynamic sensor designed to automatically optimize patients every week and, more importantly, while the patient is active, providing real-life optimization. The clinically proven SonR^® algorithm has demonstrated a 35% risk reduction in heart failure hospitalization.⁴

In addition, MicroPort^® CRM ICDs and CRT-Ds devices incorporate advanced technology with low current consumption, resulting in no compromise on the device longevity. TALENTIA^™ and ENERGYA^™ with the world's greatest projected longevity make them the longest-lasting defibrillators on the market.^5,6

About Implantable Cardiac Defibrillators (ICDs)

Implantable Cardiac Defibrillators (ICDs) are for use in patients with a high risk of sudden cardiac death, continuously monitoring the heart rate and helping to regulate fast and potentially life-threatening electrical problems with the heart. ICDs are connected to the heart by one or two leads, including a defibrillation lead that passes through the veins. ICDs provide pacing bursts to stop sustained ventricular tachycardia (fast heart rate), as well as 'back up' pacing in case of bradycardia (slow heart rate). They also deliver high-energy shocks through the defibrillation lead to restore a normal rhythm within seconds when the electrical activity of the heart deteriorates into ventricular fibrillation.

About Cardiac Resynchronization Therapy (CRT)

CRT therapy is indicated in heart failure patients with cardiac desynchronization. The CRT devices are implanted under the skin, in the chest area, and are connected to the heart by three transvenous pacing leads that conduct electrical impulses to pace the heart. The pacing leads are positioned in the right atrium, right ventricle and left ventricle. The electric stimulation of the cardiac chambers triggering their contractions is synchronized in order to restore a better pumping efficiency of the heart. The CRT therapy has been demonstrated to improve survival and quality of life, and to reduce hospitalization in heart failure patients.⁷

About MicroPort^® CRM

MicroPort® CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM) with global headquarters in Clamart, near Paris, France and an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853). With over 60 years of expertise and innovations, MicroPort® CRM develops, manufactures, and commercializes cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure, globally. These state-of-the-art products are manufactured in Clamart, France, Saluggia, Italy, and in Santo Domingo, Dominican Republic. MicroPort® CRM also distributes MicroPort® solutions in Interventional Cardiology and Electrophysiology in Europe.

For more information, please visit www.microport.com.

References:

1. Bluetooth is a registered trademark of Bluetooth SIG, Inc

2. Dichtl W. et al., Low rates of inappropriate shocks in contemporary real-world implantable cardioverter defibrillator patients: the CARAT observational study. EP Europace, Volume 25, Issue 9, September 2023, euad186, https://doi.org/10.1093/europa...

3. MicroPort CRM MRI Solutions Manuals available online at microportmanuals.com

4. Brugada J., et al. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. Eur. Heart J 2017; 38(10):730-8

5. Refer to user manual supplied with the device for complete instructions for use

6. Munawar DA et al. Predicted longevity of contemporary cardiac implantable electronic devices: A call for industry-wide "standardized" reporting. Heart Rhythm. 2018 Dec;15(12):1756-1763.

7. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-1853

Public link

Please use the above public link if you want to share this noodl on another website.